Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 10.55 below Lipocine Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 93 other companies have achieved higher Quick Ratio than Lipocine Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 172 to 412.

Explain Quick Ratio?
How much Cash & cash equivalents LPCN�s has?
What are LPCN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LPCN/financial-strength

https://api.csimarket.com/api/v1/companies/LPCN/fundamentals

https://api.csimarket.com/api/v1/companies/LPCN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

LPCN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	5.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	41.8 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	10.55	Subscribe	Subscribe	Subscribe	Subscribe
LPCN's Total Ranking	# 412	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-1.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-7.78 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 94
Healthcare Sector	# 142
Overall Market	# 412

Quick Ratio Statistics
High	Average	Low
943.6	36.06	0
(Sep 30 2012)		(Jun 30 2013)

Financial Statements
Lipocine Inc 's Current Liabilities	$ 2 Millions	Visit LPCN's Balance sheet
Lipocine Inc 's Cash & cash equivalent	$ 21 Millions	Visit LPCN's Balance sheet
Source of LPCN's Sales		Visit LPCN's Sales by Geography

Cumulative Lipocine Inc 's Quick Ratio

LPCN's Quick Ratio for the trailling 12 Months

LPCN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	47.9 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	13.39 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	9.21	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3804	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	1.14 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	8.1 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to LPCN Financial Strength Comparisons >> Go to Compare LPCN Quick Ratio to its Competitors

News about Lipocine Inc Quick Ratio

Lipocines Breakthrough Bioequivalence Study Results Pave the Way for Revolutionary Pharmacological Treatment

Lipocine Inc., a renowned biopharmaceutical company, has recently announced groundbreaking results from various studies, demonstrating the bioequivalence of its oral drug candidate, LPCN 1154, to the intravenous (IV) form of brexanolone. These results have the potential to revolutionize the treatment approach for postpartum depression (PPD) and other related conditions. In this article, we will delve into the significance of these findings and their potential impact on the pharmaceutical industry.Bioequivalence Study Results:In a pivotal pharmacokinetic (PK) study, Lipocine successfully demonstrated bioequivalence of its oral formulation of LPCN 1154 compared to the IV form of brexanolone. The positive topline results obtained from this study are monumental, as they validate the effectiveness of LPCN 1154 as an alternative treatment for PPD. This pioneering drug, developed using Lipocine s proprietary technology platform, has shown the potential to augment therapeutic options for patients suffering from this debilitating condition.

On the trailing twelve months basis LPCN Cash & cash equivalent soared by 41.8 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Lipocine Inc 's Quick Ratio to 9.21, Quick Ratio remained below LPCN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Lipocine Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2542 to 3804.

Explain Quick Ratio?
How much Cash & cash equivalents LPCN�s has?
What are LPCN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 431
Healthcare Sector	# 879
Within the Market	# 3804

trailing twelve months Quick Ratio Statistics
High	Average	Low
317.27	12.16	0.98
(Jun 30 2013)		(Sep 30 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Latigo Biotherapeutics, Inc.	28.73	$ 401.241 Millions	$ 13.964 Millions
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Relmada Therapeutics Inc	19.30	$ 202.123 Millions	$ 10.474 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Equillium Inc	18.92	$ 53.322 Millions	$ 2.819 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Sellas Life Sciences Group Inc	14.51	$ 134.711 Millions	$ 9.286 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions

Date modified: 2026-11-06T12:59:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.